Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tragara Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7629
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activity, resulting to the depletion of the key cancer cell survival protein, c-Myc. Overexpression of the MYC oncogene is used for the treatment of glioblastoma and hepatocellular carcinoma. The company is backed by life sciences investors, including Domain Associates, Lee’s Pharma, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest. Tragara Pharmaceuticals is headquartered in Carlsbad, California, the US.

Tragara Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Tragara Pharma Raises USD3.3 Million in Venture Financing 10
Tragara Pharma Raises USD13 Million in Series C Financing 11
Tragara Pharma Raises USD1.2 Million in Financing Round 13
Tragara Pharma Raises US$12 Million In Extended Series B Financing 14
Tragara Pharma Raises US$4 Million In Venture Financing 16
Licensing Agreements 17
Lee’s Pharma Enters into Licensing Agreement with Tragara Pharma 17
Tragara Pharmaceuticals Inc – Key Competitors 18
Tragara Pharmaceuticals Inc – Key Employees 19
Tragara Pharmaceuticals Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tragara Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tragara Pharma Raises USD3.3 Million in Venture Financing 10
Tragara Pharma Raises USD13 Million in Series C Financing 11
Tragara Pharma Raises USD1.2 Million in Financing Round 13
Tragara Pharma Raises US$12 Million In Extended Series B Financing 14
Tragara Pharma Raises US$4 Million In Venture Financing 16
Lee's Pharma Enters into Licensing Agreement with Tragara Pharma 17
Tragara Pharmaceuticals Inc, Key Competitors 18
Tragara Pharmaceuticals Inc, Key Employees 19

List of Figures
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tragara Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Andromeda Metals Ltd (ADN):企業の財務・戦略的SWOT分析
    Summary Andromeda Metals Ltd (Andromeda), formerly Adelaide Resources Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration and development of gold, halloysite-kaolin, lithium, and copper deposits in Australia. Its projects include Moonta …
  • UGL Ltd:企業の戦略的SWOT分析
    UGL Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Pronto Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary Pronto Diagnostics Ltd (PDL) is a medical device company that offers molecular diagnostic products and services. The company develops, produces and distributes SNP-detection kits providing assays for detecting polymorphisms in DNA sequences with genetic diseases and predisposition to disease …
  • Royal Mail plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Renault SA:企業の戦略・SWOT・財務情報
    Renault SA - Strategy, SWOT and Corporate Finance Report Summary Renault SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Polyplus-Transfection SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Polyplus-Transfection SA (Polyplus) is a biotechnology company that develops and markets solutions for in vivo and in vitro delivery of nucleic acids in research, bioproduction and therapeutics. The company develops RNA interference such as STICKY SIRNA and SIRNAPLUS for in vivo research. It …
  • Celsense Inc-医療機器分野:企業M&A・提携分析
    Summary Celsense Inc (Celsense) is a biotechnology company that develops magnetic resonance imaging detection products. The company’s products include v-sense, cell sense and voxel tracker. Its v-sense product is used to detect a range of lesions and diseases where inflammation is a hallmark such as …
  • Strategic Oil & Gas Ltd (SOG):企業の財務・戦略的SWOT分析
    Summary Strategic Oil & Gas Ltd (Strategic Oil & Gas) is an upstream oil and gas exploration and development company. The company acquires, explores, operates, manages, and develops crude oil and natural gas assets. It holds interests and operates its oil and gas exploration projects such as Marlowe …
  • Krka dd Novo Mesto (KRKG):企業の財務・戦略的SWOT分析
    Summary Krka dd Novo Mesto (Krka) is a manufacturer and distributor of pharmaceutical products. The company provides prescription pharmaceuticals, non-prescription products, and animal health products. It offers prescription products for cardiovascular diseases, diseases of alimentary tract and meta …
  • Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析
    Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PT Pertamina (Persero):企業の戦略的SWOT分析
    PT Pertamina (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Novant Health Inc:企業の戦略的SWOT分析
    Novant Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Alliant Energy Corporation (LNT)-エネルギー分野:企業M&A・提携分析
    Summary Alliant Energy Corporation (Alliant Energy) is an energy utility holding company. Through subsidiaries, it carries out generation and distribution of electricity and distribution and transportation of natural gas. The company operates through Interstate Power and Light Company (IPL) and Wisc …
  • RWE AG (RWE):電力:M&Aディール及び事業提携情報
    Summary RWE AG (RWE) is an energy company. It has presence in the energy value chain, from lignite production and electricity generation, to energy trading and operation of distribution networks, and supply of electricity, gas and energy solutions. The company produces electricity using conventional …
  • Agros Development Company “Proodos” Public Ltd:企業の戦略・SWOT・財務情報
    Agros Development Company “Proodos” Public Ltd - Strategy, SWOT and Corporate Finance Report Summary Agros Development Company “Proodos” Public Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Brown Advisory Inc:企業の戦略・SWOT・財務分析
    Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report Summary Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CellSeed Inc (7776):企業の財務・戦略的SWOT分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • MagForce AG (MF6):企業の財務・戦略的SWOT分析
    Summary MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas …
  • Lancaster Colony Corporation:企業の戦略・SWOT・財務情報
    Lancaster Colony Corporation - Strategy, SWOT and Corporate Finance Report Summary Lancaster Colony Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Zygo Corporation:企業の戦略的SWOT分析
    Zygo Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆